DealsJul 29, 2026, 04:12 PM
Xencor to receive $105M from Alexion in royalty settlement
AI Summary
Xencor, Inc. has entered into a settlement agreement with Alexion Pharma International Operations Limited, resolving a commercial dispute related to U.S. royalties on Ultomiris®. Under the agreement, Xencor will receive an aggregate of $105 million, paid in two equal installments of $52.5 million, with the first payment expected in August 2026. This settlement eliminates Alexion's future obligation for U.S. Ultomiris royalties, while ex-U.S. royalties remain unaffected. The company also announced that, based on current operating plans, it expects to have sufficient cash to fund research and development programs and operations through 2028.
Key Highlights
- Xencor to receive $105 million from Alexion in a settlement agreement.
- First payment of $52.5 million is anticipated in August 2026.
- Second payment of $52.5 million is due within 14 days of the one-year anniversary of the agreement.
- The settlement resolves a commercial dispute regarding U.S. royalties on Ultomiris®.
- Alexion will have no further obligation to pay royalties on U.S. sales of Ultomiris.
- Receipt of royalties on ex-U.S. sales of Ultomiris remains unchanged.
- Xencor expects to have cash to fund operations and R&D programs through 2028.
Price Impact
More from XNCR